Richard Barnard

Statistics

Publications

Citations

471

H-Index

Active since

2001

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Oxford

Richard Barnard is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in antiretroviral therapy, hiv reservoir suppression, and latency reversal therapy.

ORCID

Publications per year

2001–2020

Publications

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

Sarah Fidler, Wolfgang Stöhr, Lucy Dorrell et al. · The Lancet · 2020 · 138 citations

Public Health, Infectious Disease Control, Pharmacotherapy +14

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4<sup>+</sup>T Cells

Deanna A. Kulpa, Aarthi Talla, Jessica H. Brehm et al. · Journal of Virology · 2019 · 86 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

Genevieve Clutton, Yinyan Xu, Pedro L. Baldoni et al. · Scientific Reports · 2016 · 72 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer

Charles Zammit, Richard Barnard, Jennifer J. Gomm et al. · The Journal of Pathology · 2001 · 58 citations

Medicine, Molecular Biology, Oncology +14

Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics

Eric Lawitz, Mark Sulkowski, Ira M. Jacobson et al. · Antiviral Research · 2013 · 33 citations

Medicine, Infectious Diseases, Pharmacotherapy +14

1–5 of 10